Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - oxaliplatin, quantity: 100 mg - injection, powder for - excipient ingredients: lactose monohydrate - oxaliplatin is indicated for adjuvant treatment of stage iii (duke's c) colon cancer, in combination with a fluoropyrimidine agent,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for the treatment of patients with advanced oesophagogastric cancer

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - oxaliplatin, quantity: 200 mg - injection, concentrated - excipient ingredients: water for injections - oxaliplatin is indicated for adjuvant treatment of stage iii (duke's c) colon cancer, in combination with a fluoropyrimidine agent,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for the treatment of patients with advanced oesophagogastric cancer

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - oxaliplatin, quantity: 100 mg - injection, concentrated - excipient ingredients: water for injections - oxaliplatin is indicated for adjuvant treatment of stage iii (duke's c) colon cancer, in combination with a fluoropyrimidine agent,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for the treatment of patients with advanced oesophagogastric cancer

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - oxaliplatin, quantity: 200 mg - injection, concentrated - excipient ingredients: water for injections - oxaliplatin is indicated for adjuvant treatment of stage iii (duke's c) colon cancer, in combination with a fluoropyrimidine agent,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for the treatment of patients with advanced oesophagogastric cancer

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - oxaliplatin, quantity: 100 mg - injection, concentrated - excipient ingredients: water for injections - oxaliplatin is indicated for adjuvant treatment of stage iii (duke's c) colon cancer, in combination with a fluoropyrimidine agent,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for the treatment of patients with advanced oesophagogastric cancer

United States - English - NLM (National Library of Medicine)

bluepoint laboratories - oxaliplatin (unii: 04zr38536j) (oxaliplatin - unii:04zr38536j) - oxaliplatin 5 mg in 1 ml - oxaliplatin injection, used in combination with infusional 5-fluorouracil/leucovorin, is indicated for: oxaliplatin injection should not be administered to patients with a history of known allergy to oxaliplatin or other platinum compounds [see warnings and precautions (5.1)] . pregnancy category d based on direct interaction with dna, oxaliplatin may cause fetal harm when administered to a pregnant woman. there are no adequate and well-controlled studies of oxaliplatin injection in pregnant women. reproductive toxicity studies in rats demonstrated adverse effects on fertility and embryo-fetal development at maternal doses that were below the recommended human dose based on body surface area. if this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. women of childbearing potential should be advised to avoid becoming pregnant and use effective contraception while receiving treatment with oxaliplatin inje

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - oxaliplatin (unii: 04zr38536j) (oxaliplatin - unii:04zr38536j) - oxaliplatin 5 mg in 1 ml - oxaliplatin injection, in combination with infusional fluorouracil and leucovorin, is indicated for: oxaliplatin is contraindicated in patients with a history of a hypersensitivity reaction to oxaliplatin or other platinum-based drugs. reactions have included anaphylaxis [see warnings and precautions (5.1)]. risk summary based on its direct interaction with dna, oxaliplatin can cause fetal harm when administered to a pregnant woman. the available human data do not establish the presence or absence of major birth defects or miscarriage related to the use of oxaliplatin. reproductive toxicity studies demonstrated adverse effects on embryo-fetal development in rats at maternal doses that were below the recommended human dose based on body surface area (see data) . advise a pregnant woman of the potential risk to a fetus. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. data animal d

United States - English - NLM (National Library of Medicine)

qilu pharmaceutical co., ltd. - oxaliplatin (unii: 04zr38536j) (oxaliplatin - unii:04zr38536j) - oxaliplatin injection usp, in combination with infusional fluorouracil and leucovorin, is indicated for: -   adjuvant treatment of stage iii colon cancer in patients who have undergone complete resection of the primary tumor. -   treatment of advanced colorectal cancer. oxaliplatin injection is contraindicated in patients with a history of a hypersensitivity reaction to oxaliplatin or other platinum-based drugs. reactions have included anaphylaxis [see warnings and precautions (5.1)] . risk summary based on its direct interaction with dna, oxaliplatin injection can cause fetal harm when administered to a pregnant woman. the available human data do not establish the presence or absence of major birth defects or miscarriage related to the use of oxaliplatin injection. reproductive toxicity studies demonstrated adverse effects on embryo-fetal development in rats at maternal doses that were below the recommended human dose based on body surface area (see data) . advise a pregnant woman of the potential risk to a

Canada - English - Health Canada

actavis pharma company - oxaliplatin - powder for solution - 50mg - oxaliplatin 50mg - antineoplastic agents

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية بيتا - beta drug store - oxaliplatin 50 mg/vial - 50 mg/vial